Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1001/jama.2013.282835 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effects of Vitamin D and Memantine on Repetitive Mild Traumatic Brain Injury via mTOR, TRPM2, and GABA Expression Levels on Juvenile Rats.
Turk Neurosurg
November 2024
Van Yuzuncu Yil University, Faculty of Medicine, Department of Neurosurgery, Van, Türkiye.
Article Synopsis
- The study aimed to evaluate how vitamin D and memantine influence recovery in juvenile rats following repetitive brain injuries (rTBI) and to explore the mechanisms behind these effects.
- Juvenile rats were divided into seven groups receiving different treatments, including sham surgery, trauma alone, and various combinations of memantine and vitamin D before or after trauma, with analyses conducted on brain tissues and blood samples to assess injury markers.
- Results showed that trauma increased injury markers, but combination treatments using both vitamin D and memantine yielded the most significant therapeutic effects, particularly in group receiving both supplements before and after the injury.
Effect of long-term pharmacological treatments on Alzheimer disease: A systematic review and network meta-analysis.
Medicine (Baltimore)
September 2024
Department of Rehabilitation Medicine, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Sichuan, China.
Background: To analyze and compare the pharmacological treatments for Alzheimer disease (AD), we will conduct a systematic review and network meta-analysis focusing on their efficacy and safety over a duration exceeding 1 year.
Methods: We searched the databases of PubMed, Scopus, EMBASE, Web of Science, the Cochrane Central Register of Controlled Trials, and CNKI until July 30, 2023, for randomized controlled trials (RCTs) evaluating pharmacological treatments for AD.
Results: Seventeen RCTs, comprising 7214 participants, investigated the efficacy of the following drugs: Donepezil, Rivastigmine, Galantamine, Memantine, Ginkgo biloba extract (EGb), Atorvastatin-calcium and Vitamin B in the treatment of AD.
Alzheimer Disease: Treatment of Cognitive and Functional Symptoms.
Am Fam Physician
September 2024
Loma Linda University School of Medicine, California.
Alzheimer disease is a progressive, neurodegenerative disorder characterized by the accumulation of amyloid beta plaques and hyperphosphorylated tau proteins. Alzheimer disease affects cognitive function, leading to memory loss and impairment in activities of daily living. Approximately 6.
View Article and Find Full Text PDFA Review of Recent Advances in the Management of Alzheimer's Disease.
Cureus
April 2024
Department of Biomedical Education, California Health Sciences University College of Osteopathic Medicine, Clovis, USA.
Article Synopsis
- Alzheimer's disease (AD) is a prevalent neurodegenerative disorder and a significant challenge for public health, with ongoing research into its causes and treatments.
- The article discusses the key mechanisms of neuronal damage in AD and critically evaluates various pharmacological therapies, including established treatments like cholinesterase inhibitors and novel monoclonal antibodies.
- It also explores additional therapeutic approaches such as nutritional supplements and drugs targeting inflammation and diabetes, highlighting recent advancements in the search for effective AD management.
Dementia: Management and Controversies in Management.
FP Essent
November 2023
University of Iowa College of Pharmacy, Iowa City, IA.
Dementia management requires individualized patient encounters that focus on education and realistic expectations. Numerous vitamins and supplements are promoted for memory enhancement, but they lack evidence to support their use. Nonpharmacotherapy should be used through all stages of dementia.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!